Lepodisiran Clinical Trials (2026): 2 Studies for Atherosclerotic Cardiovascular Disease (ASCVD) & Elevated Lp(a)
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
2 Lepodisiran clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 2 indications (including Atherosclerotic Cardiovascular Disease (ASCVD) & Elevated Lp(a)) and 17,333 total planned enrollment. 1 Phase 3 Lepodisiran trial are listed. Most recent activity: NCT06292013 (Mar 2029).
Lepodisiran clinical trials at a glance: phase × recruitment status
| Phase | active not recruiting | Total |
|---|---|---|
| P1 | 1 | 1 |
| P3 | 1 | 1 |
Lepodisiran clinical trials by indication
Liver Dysfunction (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06916078 | LY3819469 | P1 | active not recruiting | A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function |
Atherosclerotic Cardiovascular Disease (ASCVD) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06292013 | — | P3 | active not recruiting | A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
All Lepodisiran trials (2)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06292013 | A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) | P3 | active not recruiting | 17,300 | Eli Lilly and Company | Mar 2024 | |
| NCT06916078 | LY3819469 | A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function | P1 | active not recruiting | 33 | Eli Lilly and Company | Apr 2025 |
Lepodisiran clinical trials: frequently asked questions
- How many Lepodisiran clinical trials are there?
- 2 Lepodisiran clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov.
- Are Lepodisiran clinical trials recruiting in 2026?
- No active Lepodisiran trials are recruiting on ClinicalTrials.gov as of the current AACT refresh. Trials may resume; this page is updated daily.
- What conditions is Lepodisiran being studied for?
- Lepodisiran is being studied for Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a), Healthy, Liver Dysfunction. The trials are grouped by indication on this page.
- What phase is Lepodisiran in?
- Lepodisiran clinical trials span 1 Phase 3, 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Lepodisiran clinical trials?
- The lead sponsor across the most Lepodisiran trials is Eli Lilly and Company. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Lepodisiranas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: